Talazoparib: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 40 heavily pretreated patients with locally advanced or metastatic solid tumors showed that once-daily

Read the full 222 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE